Aviko and Neutron team up to advance boron neutron capture therapy
Privately-held US firms Aviko Radiopharmaceuticals and Neutron Therapeutics have announced the formation of a strategic partnership to advance boron neutron capture therapy (BNCT) to treat cancer.
Aviko Radiopharmaceuticals is a biotech founded by investment management firm Deerfield Management developing medicines to unlock the potential of BNCT, while Neutron is a provider of accelerator-based neutron systems for targeted radiation therapy of solid tumors.
"BNCT has demonstrated the ability to eradicate tumors in as few as one or two treatments, while minimizing damage to healthy tissue"The partnership aligns the companies’ efforts to build the first BNCT treatment center in the USA and to establish additional BNCT facilities through collaborations with premier academic medical centers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze